Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

BALLERUP, Denmark I July 23, 2025 I LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...